Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.
P/E ratio for Vaxart, Inc. (VXRT)
P/E ratio as of 2023: -1.01
According to Vaxart, Inc.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -1.01. At the end of 2022 the company had a P/E ratio of -1.14.
P/E ratio history for Vaxart, Inc. from 1985 to 2023
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2023 | -1.01 |
| 2022 | -1.14 |
| 2021 | -10.81 |
| 2020 | -15.65 |
| 2019 | -0.40 |
| 2018 | -0.66 |
| 2017 | -1.80 |
| 2016 | -0.88 |
| 2015 | -2.13 |
| 2014 | -3.83 |
| 2013 | -8.12 |
| 2012 | -10.46 |
| 2011 | -17.57 |
| 2010 | 285.15 |
| 2009 | -13.03 |
| 2008 | -9.02 |
| 2007 | 4.83 |
| 2006 | -7.04 |
| 2005 | -1.58 |
| 2004 | -17.56 |
| 2003 | -85.00 |
| 2002 | 117.66 |
| 2001 | 3.99 |
| 2000 | 38.84 |
| 1999 | 48.96 |
| 1998 | -4.30 |
| 1997 | -10.64 |
| 1996 | 23.03 |
| 1995 | -20.51 |
| 1994 | 16.70 |
| 1993 | 13.01 |
| 1992 | -70.31 |
| 1991 | 23.66 |
| 1990 | 6.70 |
| 1989 | 14.06 |
| 1988 | 61.30 |
| 1987 | 35.42 |
| 1986 | 22.92 |
| 1985 | 9.09 |